S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
Log in

NASDAQ:ETTX - Entasis Therapeutics Stock Price, Forecast & News

$2.61
-0.14 (-5.09 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$2.54
Now: $2.61
$2.84
50-Day Range
$1.99
MA: $4.39
$5.56
52-Week Range
$1.75
Now: $2.61
$9.25
Volume9,800 shs
Average Volume20,844 shs
Market Capitalization$34.69 million
P/E RatioN/A
Dividend YieldN/A
Beta2.06
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. Entasis Therapeutics Holdings was founded in March 2018 and is headquartered in Waltham, MA.
Read More

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ETTX
CUSIPN/A
CIKN/A
Phone781-810-0120

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7 million
Book Value$3.17 per share

Profitability

Net Income$-43,850,000.00

Miscellaneous

EmployeesN/A
Market Cap$34.69 million
Next Earnings Date5/12/2020 (Estimated)
OptionableNot Optionable

Receive ETTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ETTX and its competitors with MarketBeat's FREE daily newsletter.


Entasis Therapeutics (NASDAQ:ETTX) Frequently Asked Questions

How has Entasis Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Entasis Therapeutics' stock was trading at $4.13 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ETTX shares have decreased by 36.8% and is now trading at $2.61. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Entasis Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entasis Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Entasis Therapeutics.

When is Entasis Therapeutics' next earnings date?

Entasis Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Entasis Therapeutics.

How were Entasis Therapeutics' earnings last quarter?

Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) posted its quarterly earnings data on Wednesday, March, 11th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.65) by $0.41. View Entasis Therapeutics' earnings history.

What price target have analysts set for ETTX?

4 analysts have issued twelve-month price objectives for Entasis Therapeutics' shares. Their forecasts range from $14.00 to $19.00. On average, they anticipate Entasis Therapeutics' stock price to reach $16.25 in the next twelve months. This suggests a possible upside of 522.6% from the stock's current price. View analysts' price targets for Entasis Therapeutics.

Has Entasis Therapeutics been receiving favorable news coverage?

News headlines about ETTX stock have trended somewhat negative on Monday, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Entasis Therapeutics earned a news impact score of -1.6 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View the latest news aboutEntasis Therapeutics.

Are investors shorting Entasis Therapeutics?

Entasis Therapeutics saw a increase in short interest in March. As of March 13th, there was short interest totaling 36,600 shares, an increase of 15.5% from the February 27th total of 31,700 shares. Based on an average daily trading volume, of 13,400 shares, the short-interest ratio is currently 2.7 days. Currently, 1.4% of the company's shares are short sold. View Entasis Therapeutics' Current Options Chain.

Who are some of Entasis Therapeutics' key competitors?

What other stocks do shareholders of Entasis Therapeutics own?

Who are Entasis Therapeutics' key executives?

Entasis Therapeutics' management team includes the following people:
  • Manoussos Perros, President, Chief Executive Officer & Director
  • Mike Gutch, Chief Financial Officer & Chief Business Officer
  • Ruben Tommasi, Chief Scientific Officer
  • Robin Isaacs, Chief Medical Officer
  • John Mueller, Chief Development Officer

When did Entasis Therapeutics IPO?

(ETTX) raised $75 million in an initial public offering on Wednesday, September 26th 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Credit Suisse and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush PacGrow were co-managers.

What is Entasis Therapeutics' stock symbol?

Entasis Therapeutics trades on the NASDAQ under the ticker symbol "ETTX."

Who are Entasis Therapeutics' major shareholders?

Entasis Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Eventide Asset Management LLC (6.62%) and Renaissance Technologies LLC (0.19%). Company insiders that own Entasis Therapeutics stock include Group Holdings (Sbs) Advis Tpg, Holdings A/S Novo and Nicholas Galakatos. View institutional ownership trends for Entasis Therapeutics.

Which major investors are buying Entasis Therapeutics stock?

ETTX stock was purchased by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, and Renaissance Technologies LLC. Company insiders that have bought Entasis Therapeutics stock in the last two years include Group Holdings (Sbs) Advis Tpg, Holdings A/S Novo, and Nicholas Galakatos. View insider buying and selling activity for Entasis Therapeutics.

How do I buy shares of Entasis Therapeutics?

Shares of ETTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Entasis Therapeutics' stock price today?

One share of ETTX stock can currently be purchased for approximately $2.61.

How big of a company is Entasis Therapeutics?

Entasis Therapeutics has a market capitalization of $34.69 million and generates $7 million in revenue each year. The company earns $-43,850,000.00 in net income (profit) each year or ($3.33) on an earnings per share basis.  View additional information about Entasis Therapeutics.

What is Entasis Therapeutics' official website?

The official website for Entasis Therapeutics is http://www.entasistx.com/.

How can I contact Entasis Therapeutics?

Entasis Therapeutics' mailing address is 35 GATEHOUSE DRIVE, WALTHAM MA, 02451. The company can be reached via phone at 781-810-0120 or via email at [email protected]


MarketBeat Community Rating for Entasis Therapeutics (NASDAQ ETTX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  153
MarketBeat's community ratings are surveys of what our community members think about Entasis Therapeutics and other stocks. Vote "Outperform" if you believe ETTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ETTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Featured Article: Green Investing

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel